[144] QUEST DIAGNOSTICS INC SEC Filing

Rhea-AI Filing Summary

Quest Diagnostics (DGX) filed a Form 144 notifying a proposed sale of 28,288 common shares through Fidelity Brokerage Services LLC on 09/23/2025 on the NYSE. The filing lists an aggregate market value of $5,293,313.43 and reports 111,823,441 shares outstanding, indicating the sale represents a very small fraction of total shares. The shares are reported as acquired under an option granted 02/19/2018 with acquisition and payment dated 09/23/2025 and payment in cash. The filer certifies they are unaware of undisclosed material adverse information and the notice contains the standard attestation language required by Rule 144.

Positive

• Filing provides clear compliance details including broker, sale date, acquisition date, option grant date, and payment method
• Transaction size is immaterial relative to the issuer's reported 111,823,441 shares outstanding (~0.025%)
• Filer includes required attestation that no undisclosed material adverse information is known

Negative

• None.

Insights

Securities Analyst

TL;DR Small scheduled sale of 28,288 shares (≈0.025% of outstanding) via Fidelity, unlikely to be material to DGX shareholders.

The filing documents a routine Rule 144 sale tied to vested options originally granted 02/19/2018. The aggregate value reported is $5.29 million, but relative to the 111.8 million shares outstanding the position is negligible. There is no disclosure of other recent sales and the filer affirms no undisclosed material adverse information. For investors, this reads as an individual insider liquidity event rather than a signal of company-wide issues.

Corporate Governance Specialist

TL;DR Proper procedural filing for an insider sale; disclosure meets Rule 144 requirements and includes the standard attestation.

The notice identifies the broker, intended sale date, acquisition method (option grant), and cash payment—covering the key compliance elements. The filing helps maintain transparency around insider dispositions but contains no governance concerns or indications of unusual timing or layering of sales. Impact on control or market liquidity is immaterial given the small share count relative to outstanding shares.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	28288	5293313.43	111823441	09/23/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/23/2025	Option Granted 02/19/2018	Issuer			28288	09/23/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Quest Diagnostics' (DGX) Form 144 disclose?

The Form 144 discloses a proposed sale of 28,288 common shares through Fidelity on 09/23/2025 with aggregate market value $5,293,313.43.

How were the shares acquired for the DGX sale?

The shares were acquired via an option granted on 02/19/2018 and are shown as acquired and to be paid for on 09/23/2025 in cash.

What broker will handle the DGX transaction?

The broker listed is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI.

How large is the proposed sale relative to DGX shares outstanding?

The sale of 28,288 shares is about 0.025% of the reported 111,823,441 shares outstanding.

Does the filer assert any undisclosed material information in the Form 144?

Yes, the filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.